- Phase 2 RADIANT study of remlifanserin for Alzheimer's disease psychosis.
Acadia Pharmaceuticals announced topline results from the phase 2 RADIANT study of remlifanserin for Alzheimer's disease psychosis. The results are described as phase 3 enabling. No specific efficacy or safety data were provided in the initial release.
One free account opens every story complete, the live board, the 30-day calendar, a watchlist and breaking alerts on your phone. No card. The wire stays free to read.